Biocon gets US FDA approval for breast cancer drug Pebrilzo, plans US launch in 2028
Posted
Via IB Times
Biocon has received US FDA approval for Pebrilzo, its biosimilar of Roche's breast cancer drug Perjeta, used to treat HER2-positive breast cancer. The company plans to launch the drug in the US in the third quarter of 2028 following a licensing agreement with Genentech.